

# Use of transdermal alcohol sensors with or without contingency management

<b>Submission date</b> 13/07/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/10/2023	<b>Overall study status</b> Completed	<input checked="" type="checkbox"/> Protocol
<b>Last Edited</b> 18/03/2025	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

This study is going to evaluate the feasibility of using Transdermal Alcohol Sensor (TAS) devices with clinical population patients (patients who are currently accessing treatment from an alcohol service for their alcohol use). The participants recruited will wear the TAS for two weeks, then complete a post-wear survey and self-report their alcohol consumption. The post-wear survey will be used to explore the user experience while the self-reported alcohol consumption will be used to determine TAS accuracy (TAS versus self-report). Half of the participants will be randomised into the contingency management group (where rewards can be earned when the target behaviour occurs). The target behaviour in this study is to keep to low or no drinking (as measured by the TAS). The other half of the participants will be in the control group without any CM rewards. The study will be conducted in SLAM NHS alcohol services and will last approximately 6 months. The study will investigate how the intended population of TAS (patients receiving alcohol treatment from their alcohol service) experiences wearing it. From this, feasibility measures will be evaluated, such as recruitment rate, the willingness of participants to enrol and staff to enrol patients, follow-up rates, response rates, and device tampering and malfunction. This is important to inform future research on the application of TAS in a larger study. This is a growing field of interest and in recent years there has been an increase in the number of TAS being developed. Currently, there is no published study, to the team's knowledge, that has conducted a feasibility study with the clinical population, who have worn a TAS over an extended length of time, specifically using the BACtrack Skyn brand of TAS. The study aims to explore the feasibility, strengths, and limitations of using a TAS to monitor alcohol consumption in individuals in treatment for AUD with or without contingency management to promote abstinence or low-level alcohol consumption.

### Who can participate?

Anyone who is over 18 years old and currently receiving alcohol treatment at one of the participating alcohol services

### What does the study involve?

The participant will express an interest in the study and if they are eligible they will be enrolled by the researcher. At enrolment, the participant will be randomised into either contingency management or control group and trained on how to wear the TAS. They will arrange all their

meetings with the researcher. There will be seven research visits in 15 days, occurring every other weekday, for example, Monday, Wednesday, Friday, Monday, Wednesday, Friday, and Monday. This is to make sure the data is downloaded from the TAS regularly to avoid data loss. At each meeting, the researcher will download the data from the TAS and record self-reported alcohol consumption, in the last meeting a post-wear survey will be completed.

All participants (control and contingency management group) will be given a £5 voucher at each meeting they attend, a £10 voucher for TAS return at the end and travel expenses reimbursed.

The contingency management group only will also be able to earn additional rewards for achieving target behaviour (low or no drinking below our set threshold, as measured by the TAS). For every day they achieve this, they can earn another £5 voucher and additional voucher bonuses for consecutive days when behaviour is achieved. When a behaviour does not occur, no rewards will be earned.

What are the possible benefits and risks of participating?

Possible benefits are that the participant may learn more about their alcohol use and reduce their alcohol consumption by wearing the TAS and earning rewards for alcohol reduction/low drinking.

Risks of participating are that previous studies have reported side effects and skin marks from wearing the TAS, particularly in hot weather. Participants will be made aware of this possibility before enrolment.

Where is the study run from?

South London (UK)

When is the study starting and how long is it expected to run for?

May 2022 to December 2023

Who is funding the study?

National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) South London (UK)

Who is the main contact?

Eileen Brobbin, eileen.brobbin@kcl.ac.uk (UK)

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Paolo Deluca

### ORCID ID

<https://orcid.org/0000-0002-9511-7230>

### Contact details

Addiction Science Building  
4 Windsor Walk

Denmark Hill  
London  
United Kingdom  
SE8 5BB  
None provided  
paolo.deluca@kcl.ac.uk

**Type(s)**  
Scientific

**Contact name**  
Miss Eileen Brobbin

**ORCID ID**  
<https://orcid.org/0000-0001-8464-4847>

**Contact details**  
Addiction Science Building  
4 Windsor Walk  
Denmark Hill  
London  
United Kingdom  
SE5 8BB  
+44 (0)7758287265  
eileen.brobbin@kcl.ac.uk

**Type(s)**  
Public

**Contact name**  
Miss Eileen Brobbin

**Contact details**  
Addiction Science Building  
4 Windsor Walk  
Denmark Hill  
London  
United Kingdom  
SE5 8BB  
+44 (0)7758287265  
eileen.brobbin@kcl.ac.uk

## **Additional identifiers**

**Integrated Research Application System (IRAS)**  
316566

**Central Portfolio Management System (CPMS)**  
57841

# Study information

## Scientific Title

Use of transdermal alcohol sensors in conjunction with contingency management to reduce alcohol consumption in people with alcohol dependence attending alcohol treatment services: Feasibility RCT

## Acronym

TAMS (Transdermal Alcohol sensor with cM Study)

## Study objectives

How feasible is the use of wearable transdermal alcohol sensors to monitor alcohol consumption in individuals receiving treatment for AUD with or without contingency management to promote abstinence or low alcohol consumption, and to what extent can wearable transdermal alcohol sensors be implemented in clinical settings?

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 31/05/2023, Cornwall and Plymouth (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 1048071; cornwallandplymouth.rec@hra.nhs.uk), ref: 23/SW/0066

## Study design

Interventional feasibility pilot randomised control trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Use of transdermal alcohol sensors with or without CM with AUD individuals.

## Interventions

South London and Maudsley NHS Foundation Trust will aid recruitment, the study will be advertised in these services, and key workers will be informed and can pass on this information via a Participant Information Sheet to patients who meet the inclusion and exclusion criteria to see if they are willing to participate. Those who are interested to participate will be asked if they consent for the service staff to pass on their name and phone number to the research team so they can be contacted about participation. The research team will then ring the potential participant: the study procedure will be explained, what is expected of them, ensure the PIS has been provided and any questions they have will be sufficiently answered.

If they are still willing to participate and meet all inclusion criteria, a date will be arranged for the researcher to meet with the patient to collect consent, baseline data and train them on wearing the device (e.g., Monday). They will also meet with the researcher every two days for around 15 minutes to download device data, complete the Time-Line Follow Back (TLFB) for that period, and, if applicable, receive contingency management (CM) from the device data (e.g.,

Wednesday, Friday, Monday, Wednesday and Friday). A final meeting will be arranged for 2 weeks after the first meeting to collect the device, post-wear survey, and TLFB.

Randomisation of participants will be done remotely by an independent statistician using a sealed envelope randomisation technique. Each time a participant enrolls, their group allocation will be revealed to the researcher. This randomisation will be completed by an independent statistician (Simon Colton). His role and responsibility in this study are to create the random allocation of each participant into the control or CM group (which I only will know on enrolment of a participant). He will not be involved in any other part of the data collection.

Throughout the two-week period, the participant will be free to contact the research team about any queries or device issues. They will be given the research team's contact number and told to contact them if they have any queries about the device or study between the hours of 9 am-5 pm. The device data download meetings will also allow participants to ask any queries they have about the device and allow for TLFB data to be collected, reducing the burden of recalling all alcohol consumption in the last meeting.

Baseline and demographic variables will have descriptive statistics reported. Analysis of the post-wear survey will be conducted, and the device data will be compared against the TLFB to address the secondary outcomes on device accuracy. Outcome measures will be compared between the control and CM groups.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Feasibility will be measured and defined by:

1. Enrolment measured using recruitment rate, the number of participants who are approached and who enrol, number of staff approached and refer participants at the recruitment stage
2. Participation measured using the number who complete the intervention, attendance rate, and compliance measured at each research visit (days 2, 4, 6, 8, 10, and 12) during the two-week study participation period
3. Device tampering/malfunction measured using the % of removed minutes, % of minutes of tampered data, % of minutes with missing data, reported battery issues, the number of meetings not attended and the number of additional meetings booked, and the number of devices returned measured at each research visit (days 2, 4, 6, 8, 10, and 12) during the two-week study participation period
4. TAS for CM implementation measured using CM vouchers provided at research visits in line with TAC device recorded data (days 2, 4, 6, 8, 10, and 12) during the two-week participation period

## **Key secondary outcome(s)**

1. TAS acceptability measured using the post-wear survey at the final research visit (day 15)
2. TAS accuracy measured using TAC device recorded data and self-report data collected at each research visit (days 2, 4, 6, 8, 10, and 12) during the two-week study period

## **Completion date**

31/12/2023

## **Eligibility**

**Key inclusion criteria**

1. Receiving alcohol treatment for an alcohol use disorder in one of the participating South London alcohol services
2. Over 18 years old and over
3. Speak English competently
4. Able to meet throughout the study period
5. Not currently participating in any other research trials
6. Willing to provide informed consent to participate

**Participant type(s)**

Service user

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

32

**Key exclusion criteria**

1. Current use of any illegal/addictive substances (excluding cannabis and smoking)
2. Under 18 years old
3. Cannot speak English

**Date of first enrolment**

05/07/2023

**Date of final enrolment**

15/12/2023

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Marina House**  
63-65 Denmark Hill  
London  
United Kingdom  
SE5 8RS

**Study participating centre**  
**The Pier Road Project**  
Health Centre  
50 Pier Rd  
Erith  
United Kingdom  
DA8 1RQ

**Study participating centre**  
**Wandsworth community drug and alcohol service**  
162 St John's Hill  
London  
United Kingdom  
SW11 1SW

## **Sponsor information**

**Organisation**  
King's College London

**ROR**  
<https://ror.org/0220mzb33>

**Organisation**  
South London and Maudsley NHS Foundation Trust

**ROR**  
<https://ror.org/015803449>

## **Funder(s)**

**Funder type**  
Government

## Funder Name

National Institute for Health Research Applied Research Collaboration South London

## Alternative Name(s)

NIHR Applied Research Collaboration South London, ARC South London, NIHR ARC South London, NIHR Applied Research Collaboration (ARC) South London, NIHR ARC SL

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Eileen Brobbin, Eileen.brobbin@kcl.ac.uk. Participant demographics, TLFB data, TAC data, and post-wear survey responses will be shared after publication. Data shared will be anonymous.

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		14/03/2025	18/03/2025	Yes	No
<a href="#">Protocol article</a>		31/07/2024	01/08/2024	Yes	No
<a href="#">Participant information sheet</a>	version 2.0	22/05/2023	24/07/2023	No	Yes
<a href="#">Thesis results</a>		01/08/2024	08/01/2025	No	No